2019 International Congress » Clinical Trials, Pharmacology and Treatment

Date: Monday, September 23, 2019

Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Meeting: 2019 International Congress

1:45pm-3:15pm: 3 Year QoL Results for PD Patients Receiving DBS: Product Surveillance Registry

M. Schiess, S. Palfi, J. Azulay, A. Lopez Rios, H. Xiong, K. Sandberg, JK. Krauss (Houston, TX, USA)

1:45pm-3:15pm: A Human Factors Study of the DopaFuse® Delivery System

J. Harmon, S. Japp, C. Long, J. Spiridigliozzi, A. Heller, B. Heller, C. King, P. Plante, R. Draper, T. Lau, E. Heller (Bala Cynwyd, PA, USA)

1:45pm-3:15pm: A Multiple Ascending-Dose Study of LY3154207, A Dopamine D1 Receptor Positive Allosteric Modulator (D1PAM)

K. Biglan, D. Wilbraham, K. Svensson, M. Tsai, W. Kielbasa (Indianapolis, IN, USA)

1:45pm-3:15pm: A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

1:45pm-3:15pm: A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

1:45pm-3:15pm: A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results

T. Simuni (Chicago, IL, USA)

1:45pm-3:15pm: A phase IIa trial studying the safety and tolerability of IRL752 in patients with Parkinson’s disease dementia

P. Svenningsson, P. Odin, N. Dizdar, F. Bergquist, A. Johansson, D. Nyholm, K. Wictorin, J. Tedroff (Uppsala, Sweden)

1:45pm-3:15pm: A pilot study of the feasibility and effects of table tennis training in Parkinson’s Disease

K. Olsson, A. Johansson, E. Franzén (Stockholm, Sweden)

1:45pm-3:15pm: A randomized clinical trial of multimodal balance training with rhythmical cues: effects on freezing of gait in Parkinson’s disease

T. Capato, N. de Vries, J. Inthout, J. Ramjith, E. Barbosa, J. Nonnekes, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1

A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

1:45pm-3:15pm: A single nigral injection of human ENGRAILED-1 induces long-lasting behavior benefit in an experimental primate model of Parkinson Disease

A. Prochiantz, E. Pioli, C. Friedel, K. Moya, E. Bézard, A. Bousseau (Paris, France)

1:45pm-3:15pm: A study for expanding application sites of rotigotine transdermal patch

S. Itaya, Y. Choh, M. Takahashi, A. Inaba, K. Orimo, Y. Ono, H. Kujirai, S. Orimo (Tokyo, Japan)

1:45pm-3:15pm: Addition of Opicapone to Safinamide in Parkinson’s Disease patients

M. Russo, C. Carrarini, F. Dono, M. Di Pietro, M. Rispoli, L. Ferri, M. Onofrj (Chieti, Italy)

1:45pm-3:15pm: Amplification of α-synuclein aggregates in cerebrospinal fluid by rapid ultrasonication-based assay

K. Kakuda, K. Ikenaka, K. Araki, Y. Kajiyama, M. So, T. Ohmichi, Y. Nagai, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

1:45pm-3:15pm: An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2

A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

1:45pm-3:15pm: Analysis of Levodopa Content in Commercial Formulations of Mucuna pruriens Seeds Used in Integrative Treatment of Parkinson’s Disease

T. Denne (Kenmore, WA, USA)

1:45pm-3:15pm: Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product

R. Hauser, S. Isaacson, A. Mittur, A. Formella, R. Patni (Tampa, FL, USA)

1:45pm-3:15pm: Application of the “5-2-1” Screening Criteria in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel: Interim Analysis from the DUOGLOBE Study

A. Antonini, J. Aldred, L. Bergmann, N. Kovács, P. Kukreja, W. Robieson, D. Standaert, KR. Chaudhuri (Padova, Italy)

1:45pm-3:15pm: Assessment of Neuropsychological Outcomes Using a New Multiple Source, Constant- Current Rechargeable Deep Brain Stimulation System for the Treatment of Parkinson’s Disease – INTREPID Study

A. Tröster, R. Jain, L. Chen, I. Study Group, M. Okun (Phoenix, AZ, USA)

1:45pm-3:15pm: Asymmetry of motor symptoms in patients with Parkinson’s Disease

Y. Trufanov, N. Svyrydova, V. Svistun, I. Harkava, H. Bondarenko, N. Zhhilova (Kyiv, Ukraine)

1:45pm-3:15pm: Atropine as Alternate Therapy for Treatment of Sialorrhea in Parksinson’s Disease

K. Papesh, J. Nguyen (Las Vegas, NV, USA)

1:45pm-3:15pm: Availability of Parkinson’s disease medicines in Ghana: a national survey

M. Cham, I. Sefah, K. Oppon, R. Odikro, C. Amenorvi, A. Malik, J. Duah, G. Pezzoli, F. Baiden, R. Cilia (Sogakope, Ghana)

1:45pm-3:15pm: Biphasic Dyskinesias in Parkinson’s disease Patients treated with Levodopa/Carbidopa Intestinal Gel: Insights from a Multicenter Retrospective Analysis

M. Marano, T. Naranian, L. Di Biase, A. Di Santo, R. Arca, G. Cossu, P. Marano, V. Di Lazzaro, A. Fasano (Rome, Italy)

1:45pm-3:15pm: Botulinum toxin type A therapy in a movement disorders unit: a 23-year experience.

M. Velez, C. Cosentino, L. Torres (Lima, Peru)

1:45pm-3:15pm: BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease

W. Poewe, K. Kieburtz, F. Stocchi, S. Oren, T. Yardeni, L. Adar, O. Rosenfeld, C. Olanow (Innsbruck, Austria)

1:45pm-3:15pm: Changes in Supine Blood Pressure with Long Term Use of Droxidopa

S. Gorny, L. Hewitt, A. Lindsten, M. Karnik-Henry, S. Kymes, A. Favit (Deerfield, IL, USA)

1:45pm-3:15pm: Changes to Speech Production after SpeechVive Treatment in Individuals with Parkinson’s Disease

J. Huber, E. Stathopoulos, J. Sussman, K. Richardson, D. Matheron, S. Snyder (West Lafayette, IN, USA)

1:45pm-3:15pm: Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?

C. Moreau, C. Laloux, C. Lachaud, E. Pioli, Q. Li, P. Pascal, L. Defebvre, R. Bordet, E. Bezard, M. Fisichella, D. Devos (Lille, France)

1:45pm-3:15pm: Deep Brain Stimulation in Early-Stage Parkinson’s Disease Provides Long-Term Rest Tremor Benefit Through Five Years

M. Hacker, M. Turchan, T. Davis, F. Phibbs, P. Hedera, P. Konrad, D. Charles (Nashville, TN, USA)

1:45pm-3:15pm: Design and Baseline Characteristics of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study

S. Chung, M. Garriga, M. Ceravolo, N. Tambasco, W. Robieson, M. Facheris, O. Sánchez-Soliño, L. Barbato (Seoul, Republic of Korea)

1:45pm-3:15pm: Design, characterization and In vivo evaluation of intranasal delivery of levodopa loaded microspere for Parkinsonism

S. Jain, A. Jain, SB. Bhargav (Sagar, India)

1:45pm-3:15pm: Development Of Anti-Parkinsonism Poly Herbal Sustained Release Formulation Composed Of Potential Traditional Plant Extracts

S. Jain, A. Jain, S. Bhargav (Sagar, India)

1:45pm-3:15pm: Directional versus omnidirectional Deep Brain Stimulation for Parkinson’s disease: Results of a prospective, blinded, multi‑center, single-arm crossover study

AS. Schnitzler, PM. Mir, MB. Brodsky, LV. Verhagen, SG. Groppa, BC. Cheeran, EK. Karst, FD. Defresne, JV. Vesper (Mainz, Germany)

1:45pm-3:15pm: Does Gait in Real Life differ between People with Parkinson’s Disease and Healthy Controls?

V. Shah, J. Mcnames, C. Curtze, M. Mancini, P. Carlson-Kuhta, J. Nutt, M. El Gohary, F. Horak (Portland, OR, USA)

1:45pm-3:15pm: Does Team-based Outpatient Palliative Care Improve Patient or Care Partner-Centered Outcomes in Parkinson’s Disease and Related Disorders?

B. Kluger, M. Katz, N. Galifianakis, K. Hall, S. Pantilat, R. Khan, C. Friedman, W. Cernik, J. Long, J. Kutner, S. Sillau, J. Miyasaki (San Francisco, CA, USA)

1:45pm-3:15pm: Dopamine receptor variants alter outcomes with levodopa in early-stage Parkinson’s disease

D. Fischer, P. Auinger, J. Goudreau, A. Cole-Strauss, K. Kieburtz, J. Elm, M. Hacker, P. Charles, J. Lipton, B. Pickut, C. Sortwell (Grand Rapids, MI, USA)

1:45pm-3:15pm: Duloxetine for pain in Parkinsons disease; A single center double blind randomised placebo controlled trial.

S. Azmin, T. Canento, B. Cruse, S. Sung, M. Farrell, A. Evans (Kuala Lumpur, Malaysia)

1:45pm-3:15pm: Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea

S. Isaacson, M. Lew, F. Pagan, R. Pahwa, D. Chary, T. Clinch (Boca Raton, FL, USA)

1:45pm-3:15pm: Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017

L. Tönges, D. Bartig, C. Krogias, D. Richter (Bochum, Germany)

1:45pm-3:15pm: Effect of an Increase in Dose of Istradefylline, an A2A Receptor Antagonist, in Levodopa (LD)-Treated Patients with Parkinson’s Disease (PD)

N. Hattori, T. Nomura, P. Salzman, H. Kitabayashi, M. Ishiuchi, K. Toyama, A. Mori (Tokyo, Japan)

1:45pm-3:15pm: Effect of Once-Daily Opicapone on the Pharmacokinetics of Repaglinide

G. Loewen, G. Liang, R. Jimenez, K. Olson, E. Smith, H. Bozigian (San Diego, CA, USA)

1:45pm-3:15pm: Effect of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Parkinson’s Disease Questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience

J. Rocha, E. Tolosa, J. Ferreira, A. Lees, O. Rascol, W. Poewe, A. Santos, D. Magalhães, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Effectiveness and safety of a herbal medication, HH368, for clinical symptoms of idiopathic Parkinson’s disease: a randomized controlled, pilot trial protocol

KH. Cho, SW. Kwon, C. Jin, WS. Jung, SK. Moon, SH. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Effects of Cognitively Challenging Agility Exercise Program on Clinical and Objective Measures in People with Parkinson’s Disease

P. Carlson-Kuhta, N. Hasegawa, SH. Jung, V. Shah, A. Ragothaman, D. Peterson, K. Smulders, L. King, M. Mancini, J. Lapidus, J. Nutt, F. Horak (Portland, OR, USA)

1:45pm-3:15pm: Effects of Virtual Reality Exercise Program using the Sony PlayStation 2 gaming platform on Balance, Emotion and Quality of Life in Patients with Parkinson’s Disease

G-H. Lee (Cheonan, Republic of Korea)

1:45pm-3:15pm: Effects of zonisamide on parkinsonism in patients with dementia with Lewy bodies by severity of cognitive dysfunction and BPSD: subgroup analysis of pooled data from two trials

K. Hasegawa, J. Goldman, T. Odawara, K. Kochi, O. Konishi, H. Maruyama, S. Toya, K. Kosaka, M. Murata, I. Mckeith (Kanagawa, Japan)

1:45pm-3:15pm: Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Idiopathic Parkinson’s disease.

M. Meloni, M. Puligheddu, M. Carta, M. Figorilli, G. Defazio (Cagliari, Italy)

1:45pm-3:15pm: Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson’s disease.

M. Meloni, M. Puligheddu, A. Cannas, M. Figorilli, G. Defazio, M. Carta (Cagliari, Italy)

1:45pm-3:15pm: Efficacy and Safety of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder in Parkinson’s Disease.

M. Meloni, M. Figorilli, M. Carta, L. Tamburrino, A. Cannas, M. Fantini, G. Defazio, M. Puligheddu (Cagliari, Italy)

1:45pm-3:15pm: Efficacy and safety of zonisamide in patients with dementia with Lewy bodies with parkinsonism: pooled analysis of phase 2 and 3 trials

J. Goldman, K. Hasegawa, T. Odawara, K. Kochi, H. Maruyama, O. Konishi, S. Toya, K. Kosaka, M. Murata, I. Mckeith (Chicago, IL, USA)

1:45pm-3:15pm: Efficacy of carbidopa/levodopa enteral suspension (CLES) in advanced Parkinson’s disease patients previously treated with deep brain stimulation (DBS) – A subgroup analysis from PROviDE study

S. Isaacson, R. Pahwa, S. Thakkar, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred (Boca Raton, FL, USA)

1:45pm-3:15pm: Efficacy of Istradefylline, an A2A Receptor Antagonist, When Added to Levodopa (LD) and Other Medications for Parkinson’s Disease (PD)

P. Lewitt, N. Hattori, A. Mori, K. Toyama, E. Ohta, P. Salzman, S. Isaacson (West Bloomfield, MI, USA)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.

A. Lees, J. Ferreira, O. Rascol, W. Poewe, F. Stocchi, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: a post-hoc analysis from combined BIPARK-I and II

A. Lees, J. Ferreira, A. Antonini, H. Reichmann, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: a post-hoc analysis from combined BIPARK-I and II

A. Lees, J. Ferreira, O. Rascol, W. Poewe, E. Tolosa, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and Clinical Global Impression of Change from the BIPARK-I double-blind experience

J. Rocha, F. Stocchi, A. Lees, J. Ferreira, W. Poewe, O. Rascol, A. Santos, D. Magalhães, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Efficacy, Safety and Tolerability of Tavapadon in Subjects With Early Stage Parkinson’s Disease

D. Gray, R. Riesenberg, J. Werth, Y. Zhang, M. Versavel, S. Duvvuri (Boston, MA, USA)

1:45pm-3:15pm: Enabling efficient use of digital health technologies to support Parkinson’s disease drug development through precompetitive collaboration

J. Cedarbaum, K. Taylor, D. Hill, R. Alexander, Y. Luo, R. Rubens, N. Zach, J. Cosman, A. Dowling, K. Fisher, L. Oliva, J. Hitchcock, M. Lawton, D. Conrado, K. Romero, M. Minchik, D. Meulien, B. Yang, M. Forman, L. Bataille, D. Dexter, J. Gallagher, M. Braxenthaler, M. Lindemann, B. Boroojerdi, G. Stebbins, B. Bloem, M. Hu, E. Dorsey, D. Stephenson (Cambridge, MA, USA)

1:45pm-3:15pm: Evaluating the Inappropriate Use of Antipsychotics in Parkinson’s Disease Psychosis Patients Within Large National US Healthcare Databases

A. Shim, V. Abler, N. Rashid (San Diego, CA, USA)

1:45pm-3:15pm: Evaluating the real-world effectiveness of carbidopa/levodopa enteral suspension (CLES) on patients with advanced Parkinson’s disease in USA: Interim-evidence from the PROviDE study

R. Pahwa, S. Isaacson, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred (Kansas City, KS, USA)

1:45pm-3:15pm: Evaluating the real-world impact of levodopa/carbidopa intestinal gel (LCIG) on motor symptoms using wearable sensors: Evidence from PROviDE study

R. Pahwa, R. Dorsey, S. Isaacson, P. Kandukuri, Y. Jalundhwala, P. Kukreja, N. Gupta, I. Pan, Y. Bao, D. Heldman (Kansas City, KS, USA)

1:45pm-3:15pm: Evaluation of neuroprotection by human ENGRAILED-1 in a chronic AAV-hα-synuclein-A53T (AAV-A53T) rat model of Parkinson Disease

A. Prochiantz, G. Porras, A. Simonnet, E. Pioli, C. Friedel, E. Bézard, A. Bousseau (Paris, France)

1:45pm-3:15pm: Evaluation of swallowing function by video-fluorography in patients with parkinsonism

S. Nogawa, Y. Chin, H. Kanke, R. Kawamura, T. Nakayama, K. Tokuoka, T. Furukawa (Tokyo, Japan)

1:45pm-3:15pm: Exploring anti-hypertensives as possible disease modifying agents in Parkinson’s disease using artificial intelligence and epidemiology

N. Visanji, S. Hensley Alford, A. Lacoste, P. Madan, I. Buleje, Y. Han, S. Spangler, L. Kalia, C. Marras (Toronto, ON, Canada)

1:45pm-3:15pm: Exploring the experience and challenges for PD STAT clinical trial participants: a qualitative study

T. North, J. Grose, V. Eyre, D. Webb, R. Chapman, A. Foggo, M. Webber, C. Carroll (Plymouth, United Kingdom)

1:45pm-3:15pm: Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions

C. Marse, J. Benoit, F. Rocher, C. Giordana (Nice, France)

1:45pm-3:15pm: First year of Opicapone for Advanced Parkinson Disease: real-life experience in a single Movement Disorders Unit

JB. Paredes, J. Poles, V. Hristova, S. Madrona, S. Argos, P. Torre, JL. Moreno, I. Moreno, JC. Castrillo, A. Canovas (Madrid, Spain)

1:45pm-3:15pm: First-In-Human Study of LY3154207, a Dopamine D1 Receptor Positive Allosteric Modulator (D1PAM)

K. Biglan, K. Svensson, W. Kielbasa (Indianapolis, IN, USA)

1:45pm-3:15pm: Formulations and evaluations of Intranasal Nose to Brain Delivery of Curcumin with resveratrol Nanoparticle for treatment of Parkisonism

A. Jain, S. Jain (Sagar, India)

1:45pm-3:15pm: GABA-A Receptor Positive Allosteric Modulators: Phase 2 Proof of Concept Studies of Brexanolone Injection and SAGE-217 in Essential Tremor

J. Paskavitz, A. Bullock, D. Nguyen, A. Smith, B. Farley, M. Quirk, I. Kaul, S. Li, A. Ellenbogen, C. Silber, J. Doherty, H. Colquhoun, S. Kanes (Cambridge, MA, USA)

1:45pm-3:15pm: GLYCOPAR – A randomized, placebo-controlled, 2-arm parallel-group superiority phase II study of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease

T. Mestre, E. Freitas, M. Lopez, A. Basndwah, L. de Oliveira, D. Al-Shorafat, Z. Alarfaz, H. Shinawi, S. Reddie, D. Mancini, J. Lui, D. Grimes, S. Fox (Ottawa, ON, Canada)

1:45pm-3:15pm: Gocovri Dose Adjustment in Elderly Parkinson’s Patients at Risk for Renal Impairment: Implications from an Exposure Simulation Model

I. Isaacson, A. Mittur, R. Patni (Boca Raton, FL, USA)

1:45pm-3:15pm: Hemiballismus-hemichorea due to ischemic stroke

AM. Magnerou, PE. Sounga Bandzouzi (Douala, Cameroon)

1:45pm-3:15pm: High Dose Botulinum Toxin Therapy: Safety, Benefit and Endurance of Efficacy

S. Chiu, B. Patel, M. Burns, J. Legacy, A. Shukla, A. Ramirez-Zamora, W. Deeb, I. Malaty (Gainesville, FL, USA)

1:45pm-3:15pm: High dose off-label Safinamide treatment in Young Onset Parkinson’s Disease patients

C. Carrarini, M. Russo, F. Barbone, F. Dono, M. Rispoli, M. Onofrj, A. Thomas (Chieti, Italy)

1:45pm-3:15pm: Identification of candidates for device-assisted therapy in Parkinson’s disease using Artificial Neural Networks

C. Valderrama Martín, L. Triguero Cueva, MJ. Pérez Navarro, CJ. Madrid Navarro, R. Calle Calle, I. Rego García, A. Mínguez Castellanos, IM. Galván León, F. Escamilla Sevilla (Granada, Spain)

1:45pm-3:15pm: Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens

F. Stocchi, W. Poewe, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

1:45pm-3:15pm: Impact of oral COMT-inhibitors on gut microbiota and biologically active microbial metabolites in patients with Parkinson’s Disease

D. Grün, V. Zimmer, J. Kauffmann, M. Unger, J. Spiegel, KU. Dillmann, A. Schwiertz, K. Faßbender, M. Fousse (Homburg, Germany)

1:45pm-3:15pm: Impact of repeated oral administration of Opicapone on the plasma pharmacokinetics of levodopa

M. Nomoto, A. Takeda, K. Iwai, A. Nishimura, N. Hattori (Ehime, Japan)

1:45pm-3:15pm: Improvements in gait deficits with peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s disease during deep brain stimulation surgery: 2-year follow-up study

G. Gera, K. Rickard, C. Crumpton, A. Borgsmiller, Z. Guduru, C. Horne, G. Qunitero (Lexington, KY, USA)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data.

F. Ikedo, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data

R. Costa, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data

F. Ikedo, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data

R. Costa, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to gender: post-hoc analysis from double-blind combined BIPARK-I and II data

F. Ikedo, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to race: post-hoc analysis from double-blind combined BIPARK-I and II data.

R. Costa, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: IncobotulinumtoxinA is effective, long lasting and well tolerated treatment of hemifacial spasm

S. Ochudlo, A. Krzak-Kubica, J. Gawryluk (Katowice, Poland)

1:45pm-3:15pm: Increasing chances of detecting a neuroprotective signal in PhI/II PD clinical trials?

S. Palfi, C. Denot, A. Bousseau, JC. Corvol (Paris, France)

1:45pm-3:15pm: Influence of baseline OFF-time in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

A. Santos, J. Ferreira, A. Lees, H. Reichmann, W. Poewe, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II.

A. Santos, J. Ferreira, A. Lees, H. Reichmann, W. Poewe, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Influence of disease duration in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

H. Gama, J. Ferreira, A. Lees, A. Antonini, O. Rascol, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Influence of disease severity in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

H. Gama, A. Lees, J. Ferreira, O. Rascol, A. Antonini, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.

A. Santos, A. Lees, J. Ferreira, O. Rascol, A. Antonini, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Intestinal Levodopa/Carbidopa Infusion as a Therapeutic Option for Freezing of Gait After Deep Brain Stimulation in Parkinson’s Disease

B. González, S. Jauma, R. Gomez, C. Marzal, M. Calopa (Hospitalet de Llobregat, Spain)

1:45pm-3:15pm: INTREPID: A 2-Year Follow-Up of a Prospective, Double Blinded, Multi-Center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant-Current Rechargeable System for Treatment of Parkinson’s Disease

J. Vitek, R. Jain, L. Chen, I. Study Group, P. Starr (Minneapolis, MN, USA)

1:45pm-3:15pm: Laboratory Performance of the DopaFuse® Delivery System

R. Draper, J. Harmon, A. Heller, B. Heller, E. Heller, C. King, T. Lau, P. Plante, J. Spiridigliozzi (Austin, TX, USA)

1:45pm-3:15pm: Lack of Notable Skin Reactions from a Novel Levodopa/Carbidopa Prodrug after 10 Days of Repeated 24-Hour Continuous Subcutaneous Infusion at the Same Administration Site

M. Facheris, X. Qi, C. Locke, M. Rosebraugh, J. Benesh (North Chicago, IL, USA)

1:45pm-3:15pm: Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study

R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, Y. Thongchuam, T. Boonmongkol, P. Garcia Ruiz (Bangkok, Thailand)

1:45pm-3:15pm: Long-term impact of Levodopa Carbidopa Intestinal Gel (LCIG) on reducing “Off” time: Results from a systematic review of studies with ≥ 12 months of follow-up

A. Antonini, P. Odin, R. Pahwa, J. Aldred, A. Alobaidi, Y. Jalundhwala, P. Kukreja, L. Bergmann, S. Inguva, Y. Bao, K. Chaudhuri (North Chicago, IL, USA)

1:45pm-3:15pm: Long-term levodopa-carbidopa intestinal infusion in Parkinson’s disease: survival and mortality

CA. Artusi, R. Balestrino, G. Imbalzano, S. Bortolani, S. Tuttobene, E. Montanaro, M. Zibetti, L. Lopiano (Torino, Italy)

1:45pm-3:15pm: Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease (PD) patients with persistent motor fluctuations: results of the 1-year open-label phase of the TOLEDO study

R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl, K. Chaudhuri, T. Henriksen, T. van Laar, D. Lockhart, A. Lees (London, United Kingdom)

1:45pm-3:15pm: Long-term safety and efficacy of rimabotulinumtoxinB in the treatment of adult sialorrhea

K. Dashtipour, S. Isaacson, M. Lew, D. Chary, T. Clinch, R. Pahwa (Boca Raton, FL, USA)

1:45pm-3:15pm: Management of Akinesia in Parkinson’s Disease with Apomorphine Subcutaneous Injection

F. Rakhimov, B. Sultanov (Tashkent, Uzbekistan)

1:45pm-3:15pm: Medical management of primary hemifacial spasm

G. Kumar, D. Kaur, A. Singh (Patna, India)

1:45pm-3:15pm: Molecular Integration in Neurological Diagnosis (MIND): A Center-Wide Approach to Improve Molecular and Genetic Characterization of Parkinson’s Disease

T. Tropea, J. Rick, N. Han, S. Rudovsky, A. Siderowf, V. van Deerlin, A. Chen-Plotkin (Philadelphia, PA, USA)

1:45pm-3:15pm: Motor assessments in HD clinical trials: Q-Motor versus the UHDRS-TMS – what did we learn from recent studies?

R. Reilmann, R. Schubert, P. Barallon, P. Pracht, B. Habbel (Muenster, Germany)

1:45pm-3:15pm: Multi-kinase Abelson (c-Abl) and Discoidin Domain Receptors (DDR1/2) inhibitors, Nilotinib, alters CSF soluble TREM2 (sTREM2) in individuals with Parkinson’s Disease

F. Pagan, M. Hebron, B. Wilmarth, Y. Torres-Yaghi, E. Mundel, N. Yusuf, C. Moussa (Washington, DC, USA)

1:45pm-3:15pm: NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson’s Disease: Study Design and Status Update

T. Simuni, B. Fiske, K. Merchant, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, C. Venuto, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff (Boston, MA, USA)

1:45pm-3:15pm: Non-Medical Switching: Impact on Movement Disorders Patients’ Access and Care

B. Kennedy, J. Peterson, D. Charles (Washington, DC, USA)

1:45pm-3:15pm: Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease

G. Hatipoglu, S. Ozkaynak (Antalya, Turkey)

1:45pm-3:15pm: Oligomeric Alpha-synuclein in Erythrocyte Membrane in Early Parkinson’s Disease

GL. Liu, C. Tian, T. Feng (Beijing, China)

1:45pm-3:15pm: Onset of action for rimabotulinumtoxinB in the treatment of adult sialorrhea

L. Bahroo, S. Isaacson, R. Pahwa, D. Chary, T. Clinch, M. Lew (Washington, DC, USA)

1:45pm-3:15pm: Open-label safety and tolerability of L-Dihydroxyphenylserine (L-DOPS) and high dose carbidopa therapy in Parkinson’s disease patients

K. Hay, K. Mcdonell, P. Trujillo, M. Donahue, N. van Wouwe, D. Claassen (Nashville, TN, USA)

1:45pm-3:15pm: Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

J. Norton, D. Fredericks, G. Alva, J. Aldred, B. Coate, D. Dekarske, M. Cantillon, R. Owen (San Deigo, CA, USA)

1:45pm-3:15pm: Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations

C. Liguori, M. Pierantozzi, R. Cerroni, NB. Mercuri, A. Stefani (Rome, Italy)

1:45pm-3:15pm: Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom

V. Leta, D. van Wamelen, A. Sauerbier, S. Jones, A. Podlewska, D. Trivedi, M. Parry, P. Odin, A. Storch, Z. Pirtošek, A. Antonini, K. Ray Chaudhuri (London, United Kingdom)

1:45pm-3:15pm: Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials

R. Hauser, O. Rascol, W. Poewe, J. Ferreira, A. Lees, O. Klepitskaya, G. Liang, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Tampa, FL, USA)

1:45pm-3:15pm: Opicapone improves motor and non-motor wearing off symptoms in Parkinson’s disease: an observational real-world study

C. Oehlwein, K. Mittmann, D. Sarkisjan, J. Baron, M. Oehlwein, K. Witt (Gera, Germany)

1:45pm-3:15pm: Opicapone odds ratio in relative OFF-time reduction: a post-hoc analysis from combined BIPARK-I and II data

J. Rocha, W. Poewe, O. Rascol, A. Lees, J. Ferreira, A. Santos, D. Magalhães, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: OPICAPONE: REAL WORLD EVIDENCE IN TOLEDO´S MOVEMENT DISORDERS UNIT

JC. Segundo-Rodríguez, N. López-Ariztegui, MI. Morales-Casado, N. García-Alvarado, A. Avila-Fernández, J. Pérez-Matos (Toledo, Spain)

1:45pm-3:15pm: Outcomes of the first-in-human study with a recombinant botulinum toxin E (rBoNT-E): safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA

L. Pons, C. Vilain, P. Picaut (Cambridge, MA, USA)

1:45pm-3:15pm: Parkinson Kinetigraph – does it change the management of PD patients?

F. Bergquist, A. Cvejtkovic, AC. Sjöström, S. Wallerstedt (Gothenburg, Sweden)

1:45pm-3:15pm: Parkinson’s disease and intermittent hypoxia training: beneficial or harmful?

M. Sharifi-Bonab, J. Sesink, B. Bloem, D. Devos, J. Deguil, C. Moreau (Nijmegen, Netherlands)

1:45pm-3:15pm: Parotitis as Adverse Event Following BoNT Injections for Sialorrhea

K. Papesh, J. Nguyen (Las Vegas, NV, USA)

1:45pm-3:15pm: Path to Prevention (P2P) – Developing a Prodromal PD Progression Biomarker Program

K. Marek, A. Siderowf, C. Coffey, T. Foroud, V. Arnedo, E. Flagg, S. Chowdhury, K. Kieburtz, L. Chahine, J. Seibyl (New Haven, CT, USA)

1:45pm-3:15pm: Pharmacokinetics of Opicapone and Effect on COMT and Levodopa Pharmacokinetics in Patients with Parkinson’s Disease

G. Loewen, P. Lewitt, C. Olanow, K. Kieburtz, G. Liang, R. Jimenez, K. Olson, E. Roberts (San Diego, CA, USA)

1:45pm-3:15pm: Pharmacological effect of adenosine A2A receptor antagonist for levodopa-induced dyskinesia associated with cellular energy homeostasis

NAO. Kanzato (Okinawa, Japan)

1:45pm-3:15pm: Polyneuropathy in patients with continuous levodopa/carbidopa intestinal gel (LCIG) infusion

KAM. Pauls, J. Toppila, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)

1:45pm-3:15pm: Population Pharmacokinetics and Pharmacodynamics of Ampreloxetine (TD-9855) in Patients with Neurogenic Orthostatic Hypotension (nOH)

A. Lo, J. Kanodia, R. Vickery, D. Bourdet (South San Francisco, CA, USA)

1:45pm-3:15pm: Practice Patterns with Onabotulinum Toxin-A for Movement disorders: South Asian Neurologist Survey

G. Kumar, P. Wadia, H. Kumar, P. K, S. Gupta, V. Goyal, A. Raza, A. Zuzek, A. Patel (Bengaluru, India)

1:45pm-3:15pm: Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease

K. Satterly, G. Davies, B. Gajera, J. Wright, H. Lin, S. Muppaneni, K. To, S. Shrewsbury, J. Hoekman (Seattle, WA, USA)

1:45pm-3:15pm: Preclinical efficacy of drugs identified by IBM-Watson for repurposing to treat L-DOPA-induced dyskinesia

N. Visanji, A. Lacoste, P. Ravenscroft, S. Spangler, S. Fox, A. Lang, J. Brotchie, T. Johnston (Toronto, ON, Canada)

1:45pm-3:15pm: Prolonged-release Melatonin for Sleep Disorders in Parkinson’s Disease: A Randomized trial

JH. Ahn, M. Kim, JK. Mun, J. Youn, S. Park, W. Jang, J. Park, E. Oh, JW. Cho, JS. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Quantitative study of subthalamic ERG potassium channels in parkinsonian discharges

C. Mahapatra, R. Manchanda (Mumbai, India)

1:45pm-3:15pm: Randomized, placebo-controlled, double-blind, two-period cross-over study to evaluate the safety, tolerability, and efficacy of a novel treatment combination for levodopa induced dyskinesia in Parkinson’s Disease (BUS-PD)

K. Chung, B. Lobb, S. O'Connor (Portland, OR, USA)

1:45pm-3:15pm: RimbotulinumtoxinB in the treatment of adult sialorrhea

S. Isaacson, W. Ondo, M. Lew, K. Dashtipour, D. Chary, T. Clinch, F. Pagan (Boca Raton, FL, USA)

1:45pm-3:15pm: Risk Thresholds of Levodopa Dose for Dyskinesia in Chinese Patients with Parkinson’s Disease: A Pilot Study

GL. Liu, T. Feng (Beijing, China)

1:45pm-3:15pm: Rivastigmine for visual hallucinations in Parkinson’s disease

T. Mierlo, E. Foncke, R. Bie (Amsterdam, Netherlands)

1:45pm-3:15pm: Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study

M. Facheris, J. Benesh, J. Streit, W. Robieson, C. Zadikoff, D. Standaert (North Chicago, IL, USA)

1:45pm-3:15pm: Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients

M. Schiess, J. Suescun, T. Ellmore, MF. Doursout, E. Furr -Stimming, Z. Mei, A. Gee (Houston, TX, USA)

1:45pm-3:15pm: Safety of Gocovri in Clinical Practice: One-year Post-launch Pharmacovigilance Data

C. Tanner, R. Pahwa, V. Vandevoorde, K. Wehrman, R. Elfont (San Francisco, CA, USA)

1:45pm-3:15pm: Safety of Iron Chelation in Patients with Brain Iron Overload

C. Fradette, T. Klopstock, L. Neumayr, I. Karin, G. Zorzi, T. Kmieć, B. Büchner, H. Steele, R. Horvath, P. Chinnery, A. Basu, C. Küpper, C. Neuhofer, F. Zibordi, N. Nardocci, A. Stilman, M. Spino, E. Vichinsky, F. Tricta (Toronto, ON, Canada)

1:45pm-3:15pm: Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients

C. Cattaneo, E. Bonizzoni, C. Keywood (Milan, Italy)

1:45pm-3:15pm: SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE

A. Vinagre-Aragón, E. Mondragón-Rezola, I. Croitoru, A. Bergareche-Yarza, JJ. Poza-Aldea, A. Olaskoaga-Caballer, M. Iridoy-Zulet, M. Ruibal-Salgado, JC. Gómez-Esteban, K. Berganzo-Corrales, B. Tijero-Merino, J. Ruiz-Martínez (San Sebastián, Spain)

1:45pm-3:15pm: Safinamide: real world evidence in Toledo´s Movement Disorders Unit

N. López-Ariztegui, MI. Morales-Casado, JC. Segundo-Rodríguez, A. Avila-Fernández, N. García-Alvarado, J. Pérez-Matos (Toledo, Spain)

1:45pm-3:15pm: Short term use of bromocriptine for treatment of Parkinson’s disease during pregnancy

D. Taylor, P. Lewitt (West Bloomfield, MI, USA)

1:45pm-3:15pm: Smartphone software for home monitoring of motor symptoms in Parkinson’s disease – The CloudUPDRS Smartphone Software in Parkinson’s (CUSSP) study

E. Menozzi, A. Jha, R. Oyekan, S. Schreglmann, A. Latorre, E. Mulroy, G. Roussos, C. Stamate, I. Daskalopoulos, J. Rothwell, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: Spectrum of motor complications in advanced Parkinson’s disease: data from a large Romanian case series evaluated for suitability for device aided therapy

J. Szász, V. Constantin, K. Orbán, L. Bancu, D. Georgescu, J. Szederjesi, A. Rácz, I. Mihály, S. Szatmári (Tirgu Mures, Romania)

1:45pm-3:15pm: Successful Treatment of Orthostatic Tremor using Perampanel

A. Wadhwa, S. Schaefer (New Haven, CT, USA)

1:45pm-3:15pm: Switching entacapone ‘non-responders’ to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARK-I study

J. Ferreira, A. Lees, W. Poewe, O. Rascol, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

1:45pm-3:15pm: Symptomatic treatment of hereditary spastic paraplegias with fampridine: a pilot study

M. Rosário, J. Ferreira, J. Ferro, L. Guedes (Lisbon, Portugal)

1:45pm-3:15pm: Systematic review of Mucuna Pruriens as a treatment for Parkinson’s disease

TH. Boonmongkol, O. Phokaewvarangkul, S. Vimolmangkang, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program

R. Hauser, D. Kremens, D. Chernick, R. Patni, J. Hubble (Tampa, FL, USA)

1:45pm-3:15pm: The effect of levodopa-carbidopa intestinal gel relative to optimized medical treatment on dyskinesia: Design and baseline characteristics for an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients (DYSCOVER Study)

E. Alvarez, C. Spanaki, E. Pekkonen, L. Manzanares, Y. Liu, O. Sánchez-Soliño, L. Barbato (Elche, Spain)

1:45pm-3:15pm: The Effects of Apomorphine infusion on Head ptosis, a case report

O. Skogar (Stockholm, Sweden)

1:45pm-3:15pm: The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program

R. Pahwa, C. Tanner, L. Zhang, R. Johnson, C. Leroue, R. Patni (Kansas City, KS, USA)

1:45pm-3:15pm: The evaluation of exosomes as a biomarker of Parkinson’s disease

Y. Ishiguro, T. Tsunemi, A. Yoroisaka, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: The French NS-PARK/FCRIN network: a 5-year balance sheet

O. Rascol, JC. Corvol, F. Durif, E. Delappina, V. Chaigneau, JP. Azulay, P. Couratier, L. Defebvre, D. Devos, P. Damier, A. Doe, S. Drapier, S. Frismand, C. Geny, C. Giordana, JL. Houeto, P. Krystkowiak, E. Magnin, D. Maltete, W. Meissner, T. Moreau, E. Moro, P. Remy, C. Thiriez, S. Thobois, C. Tranchant, F. Viallet, M. Vidailhet (Paris, France)

1:45pm-3:15pm: The relationship between sound pressure level (SPL) and speech intelligibility in Parkinson’s disease following intensive speech treatment: LSVT LOUD and LSVT ARTIC

L. Ramig, E. Levy, M. Chang, K. Forrest, G. Moya-Gale (Boulder, CO, USA)

1:45pm-3:15pm: The relationship between the motor onset and the asymmetry of motor symptoms in patients with Parkinson’s Disease

Y. Trufanov, N. Svyrydova, V. Svistun, I. Harkava, H. Bondarenko, N. Zhhilova (Kyiv, Ukraine)

1:45pm-3:15pm: The Representativity of PSP patients included in clinical trials

LL. Mariani, R. Guimarães-Costa, D. Grabli, B. Letoullec, F. Cormier, B. Degos, B. Dubois, M. Vidailhet, L. Lacomblez, JC. Corvol (Paris, France)

1:45pm-3:15pm: Transcranial Direct Current Stimolation (tDCS) on PD Patients with Freezing of Gait: Preliminary Findings

S. Scalise, G. Di Lazzaro, M. Alwardat, NB. Mercuri, M. Patera, G. Saggio, T. Schirinzi, A. Pisani (Rome, Italy)

1:45pm-3:15pm: Treatment monitoring using objective and frequent digital testing in the D1PAM (LY3154207) phase 1B Parkinson’s disease clinical trial

J. Wang, C. Battioui, Y. Li, A. Calvin, L. Wu, A. Romano, B. Miller (Indianapolis, IN, USA)

1:45pm-3:15pm: Two-year outcome of autologous peripheral nerve grafting to the substantia nigra at the time of DBS surgery in patients with Parkinson’s disease

C. van Horne, J. Quintero, J. Slevin, J. Gurwell, Z. Guduru, A. Welleford, N. El Seblani, G. Gerhardt (Lexington, KY, USA)

1:45pm-3:15pm: Unilateral delivery of cell-based therapy to the putamen and substantia nigra in patients with Parkinson’s disease who have an existing DBS system

J. Quintero, J. Slevin, Z. Guduru, J. Gurwell, G. Gerhardt, C. van Horne (Lexington, KY, USA)

1:45pm-3:15pm: Use digital sensor and deep learning to evaluate motor performance in the D1PAM (LY3154207) phase 1B Parkinson’s disease clinical trial

Y. Li, Y. Guan, J. Wang, A. Calvin, J. Kyle, B. Miller (Indianapolis, IN, USA)

1:45pm-3:15pm: Use of Inappropriate Antipsychotics Among US Long-Term Care Residents with Parkinson’s Disease Psychosis

D. Kremens, V. Abler, S. Andes, N. Rashid, A. Shim (Philadelphia, PA, USA)

1:45pm-3:15pm: Using cognitive computing to identify existing drugs with potential to stabilize mitophagy pathways associated with Parkinson’s Disease

N. Visanji, N. Moskal, G. Shi, A. Lacoste, S. Spangler, P. Lewis, A. Mcquibban (Toronto, ON, Canada)

1:45pm-3:15pm: Utilization of Monotherapy and Combination Therapies in Advanced Parkinson Disease Patients During Levodopa-Carbidopa Intestinal Gel Treatment from the COSMOS Study

A. Fasano, JC. Parra, T. Gurevich, R. Jech, N. Kovács, P. Svenningsson, J. Szász, L. Bergmann, A. Johnson, O. Sanchez-Soliño, Z. Tang, L. Vela-Desojo (Toronto, ON, Canada)

1:45pm-3:15pm: Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study

S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, W. Meissner, F. Tison, O. Rascol (Bordeaux, France)

1:45pm-3:15pm: Vortioxetine treatment of depression in Parkinson’s disease

M. Russo, C. Carrarini, F. Dono, L. Ferri, M. Di Pietro, M. Onofrj (Chieti, Italy)

1:45pm-3:15pm: Yerba mate tea (Ilex paraguariensis) exerts a neuroprotective effect on intrastriatal 6-OHDA-lesioned mice model of Parkinson’s disease

I. Taravini, G. Gomez, L. Tribbia, A. Cura, R. Rivero, M. Bernardi, J. Ferrario, B. Baldi-Coronel, O. Gershanik, E. Gatto (Gualeguaychú, Argentina)

« View all sessions from the 2019 International Congress.